Venus Remedies Peer Comparison

NSE: VENUSREM | BSE: 526953

₹1,330.20

₹-58.60 (-4.22%)

As on 28-Oct-2026IST

Market cap

₹1,775 Cr

Revenue (TTM)

₹837 Cr

P/E Ratio

14.6

P/B Ratio

2.5

Div. Yield

0.8 %

Edit

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Market cap (₹ Cr)	1,775	16,318	6,132	2,201	1,516
Revenue (₹ Cr)	837	3,330	2,289	302	301
Net Profit (₹ Cr)	121.69	720.77	313.25	42.87	45.49
Net Margin (%)	14.35	21.60	12.91	14.09	14.58
RoE (%)	17.79	18.93	12.78	12.79	18.17
Price to Earnings	14.59	23.06	19.58	51.34	33.33
Price-To-Book	2.52	3.94	2.30	6.36	6.58

Income Statement (₹ Cr)

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Operating Revenue	837.28	3,329.63	2,289.33	301.83	300.76
Total Income	847.88	3,337.47	2,425.61	304.33	311.96
Total Expenditure	659.64	2,168.88	1,923.40	211.40	239.32
EBITDA	177.64	1,160.75	365.93	90.42	61.43
Depreciation	29.63	285.40	60.25	25.45	8.53
EBIT	148.01	875.35	305.68	64.97	52.90
Interest	0.02	187.51	4.34	7.86	1.01
Other Income	10.60	7.84	136.29	2.50	11.21
Exceptional Items	0.00	-53.14	-20.79	0.00	-2.31
Profit before Tax	158.59	642.54	416.84	59.62	60.79
Provision for Tax	36.90	-78.23	103.60	16.75	15.29
Profit after Tax	121.69	720.77	313.25	42.87	45.49

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Shareholder's Funds	704.51	4,144.34	2,668.91	345.99	243.80
Minority Interest	0.00	-10.85	0.00	0.00	0.00
Non-Current Liabilities	25.50	758.48	73.11	49.82	11.83
Current Liabilities	109.56	2,681.14	433.67	119.92	39.80
Total Liabilities	853.70	7,246.72	3,938.74	481.01	329.30

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Non-Current Assets	453.28	5,578.78	1,793.21	339.65	95.52
Current Assets	362.91	1,800.86	1,196.99	160.59	165.89
Total Assets	853.70	7,246.72	3,938.74	481.01	329.30
Total Debt*	0.00	2,309.68	0.00	70.53	0.00
Net Current Assets	253.35	-880.28	763.32	40.67	126.10
Contingent Liabilities	19.86	51.57	204.54	--	22.34

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Cash From Operating Activities	155.77	537.99	200.45	49.26	46.81
Cash Flow from Investing Activities	-181.57	-369.46	-109.93	-28.35	-35.65
Cash from Financing Activities	-3.12	-313.53	-93.33	-20.96	-12.15
Net Cash Inflow / Outflow	-28.91	-145.00	-2.80	-0.05	-0.99

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
ROCE (%)	21.88	14.47	15.93	12.52	22.69
ROE (%)	17.79	18.93	12.78	12.79	18.17
ROA (%)	15.14	9.78	10.34	8.89	15.31
EBIT Margin (%)	17.68	26.29	13.35	21.53	17.59
Net Margin (%)	14.35	21.60	12.91	14.09	14.58
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Revenue Growth (%)	18.91	11.06	10.20	47.99	6.40
EBIT Growth (%)	101.16	13.71	41.66	119.64	15.67
Net Profit Growth (%)	73.03	60.98	38.96	119.78	-26.56
EPS Growth (%)	94.63	80.38	46.13	117.73	10.27
Book Value Growth (%)	18.33	36.71	8.94	14.81	17.30

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Price / Earnings	14.59	21.36	18.62	51.33	32.24
Price / Book Value	2.52	3.94	2.30	6.36	6.58
Dividend Yield (%)	0.75	0.00	1.33	0.00	2.40
EV/EBITDA	9.41	15.99	15.33	25.11	22.95
Market Cap (₹ Cr)	1,103.60	17,980.08	5,229.56	1,109.05	1,234.49

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Debt to Equity	0.00	0.10	0.00	0.10	0.00
Short term debt to equity ratio	--	0.12	--	0.07	--
Current Ratio	3.31	0.67	2.76	1.34	4.17
Quick Ratio	2.11	0.49	2.06	0.53	3.68
Interest Coverage	7,930.50	4.43	97.11	8.58	61.12

	Venus Remedies	Eris Lifesciences	FDC	Sakar Healthcare	Jagsonpal Pharma
Debtors to sales (%)	10.47	18.98	6.71	13.06	8.97
Asset Turnover	1.04	0.45	0.76	0.63	1.01
Receivable days	51.10	63.88	21.28	58.58	18.20
Inventory Days	54.51	43.27	59.64	82.38	17.89
Payable days	96.77	151.85	105.74	107.49	37.27
Cash Conversion Cycle	8.84	-44.70	-24.83	33.48	-1.18

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.